Evidence map›Paper›PMID 32393323›Full record

Trial reportJournal of hematology & oncology2020

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.

Feng Wang, Shukui Qin, Xinchen Sun, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang and 8 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hematology & oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Feng WangDepartment of Radiotherapy, The First Affiliated Hospital of Nanjing Medical College, No. 300, Guangzhou Rode, Nanjing, 210029, China.
Shukui QinDepartment of Medical Oncology, Cancer Center of Jinling Hospital, No. 34, 34 Biao, Yanggongjing Street, Nanjing, 210002, China. qinsk@csco.org.cn.
Xinchen SunDepartment of Radiotherapy, The First Affiliated Hospital of Nanjing Medical College, No. 300, Guangzhou Rode, Nanjing, 210029, China. sunxinchen@csco.org.cn.
Zhenggang RenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhiqiang MengMinimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhendong ChenDepartment of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiaoli ChaiDepartment of Intervention, Hunan Cancer Hospital, Changsha, China.
Jianping XiongDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Yuxian BaiDepartment of Medical Oncology, 3rd Affiliated Hospital of Harbin Medical University, Harbin, China.
Lin YangDepartment of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hong ZhuDepartment of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Weijia FangDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Xiaoyan LinDepartment of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
Xiaoming ChenDepartment of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, China.
Enxiao LiDepartment of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, China.
Linna WangClinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China.
Ping YanClinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China.
Jianjun ZouClinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAssociation of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an immune checkpoint inhibitor, but lack of comprehensive analyses. In this study, we conducted comprehensive analyses on RCCEP in advanced hepatocellular carcinoma (HCC) patients treated with camrelizumab monotherapy.

methodsData were derived from a Chinese nationwide, multicenter phase 2 trial of camrelizumab in pre-treated advanced HCC. The occurrence, clinicopathological characteristics, and prognostic value of RCCEP were analyzed.

resultsWith a median follow-up of 12.5 months, 145 of the 217 camrelizumab-treated patients (66.8%) experienced RCCEP (all grade 1 or 2). RCCEP occurred on the skin surface, mainly on the skin surface of head, face, and trunk. RCCEP could be divided into 5 types including "red-nevus-like," "pearl-like," "mulberry-like," "patch-like," and "tumor-like," according to the morphological features. RCCEP biopsy and pathology showed capillary endothelial hyperplasia and capillary hyperplasia in dermis. Significant association between RCCEP occurrence with higher objective response rate was observed (19.3% vs. 5.6%; one-sided p = 0.0044). Compared with those without RCCEP, patients with RCCEP had prolonged progression-free survival (median PFS; 3.2 months vs. 1.9 months; one-sided p < 0.0001) and overall survival (median OS; 17.0 months vs. 5.8 months; one-sided p < 0.0001). In multivariable analyses, the development of RCCEP was significantly associated with prolonged PFS and OS after adjusting for baseline covariates. In addition, the landmark analyses of PFS and OS were consistent with the unadjusted analysis.

conclusionsRCCEP occurred on the skin surface and was an immune response of skin capillary endothelial cells. RCCEP occurrence positively associated with outcomes of camrelizumab in advanced HCC.

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, HepatocellularCell ProliferationChinaEndothelial CellsHumansImmune Checkpoint InhibitorsLiver NeoplasmsSkinSurvival AnalysisAntibodies, Monoclonal, HumanizedcamrelizumabImmune Checkpoint InhibitorsAnti–PD-1 antibodyCamrelizumabHepatocellular carcinomaImmune-related adverse eventsReactive cutaneous capillary endothelial proliferation

Identifiers

PMID32393323
PMCPMC7216554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.